Patent cliff explains something that looks backwards at first: when AstraZeneca was reported to be exploring a takeover of Bristol Myers Squibb on August 3, 2026, AstraZeneca’s stock — the buyer, not the target — fell as much as 9%, its worst day since 2020. Bristol Myers shares climbed instead.
That’s actually the normal pattern in M&A. The company funding a deal, or taking on the risk of integrating another business, usually falls. The target, bought at a premium, usually rises. Merger arbitrage is the trade built entirely around betting on that gap closing once a deal is confirmed.
What makes this one odd is that AstraZeneca didn’t look like it needed a deal. Cancer drugs now make up roughly half its sales, and it’s targeting $80 billion in annual revenue by 2030, up from $58.7 billion last year. Analysts called the rumor “perplexing.”
Bristol Myers, on the other hand, is running straight toward a patent cliff — the point where a drug’s patent protection ends, generics flood in, and sales that looked stable drop off like a step, not a slope. Two of its drugs, blood thinner Eliquis and cancer drug Opdivo, made up about half of Bristol Myers’ revenue last year. Both lose US patent protection in 2028. In Europe, Eliquis’ exclusivity already ended in May.
That’s the logic buried in the rumor. A wide economic moat — the durable edge that protects a company’s profits — doesn’t last forever when the edge is a patent. Once the clock runs out, the fastest way back to growth is often buying someone else’s pipeline outright, even at the cost of your own stock price on the day the market finds out.
Neither company has confirmed the talks, and deals like this can stall before signing. But the size of AstraZeneca’s drop is itself a signal: investors were pricing in that they’d be the one absorbing Bristol Myers’ patent cliff, not the other way around.
Not advice. Just how I see it.